OriGene Technologies

OriGene Technologies

Sells gene-based research tools and reagents

Overview

OriGene Technologies provides gene-based research tools and reagents for academic, pharmaceutical, and biotech researchers. It sells cDNA clones, antibodies, proteins, RNAi, and lentiviral particles directly to research institutions worldwide. It differentiates itself with a very large inventory and a distributed manufacturing network that enables rapid access to a broad set of gene-based tools. Its goal is to help researchers advance gene-based science by providing reliable reagents and educational resources.

About OriGene Technologies

Simplify's Rating
Why OriGene Technologies is rated
C-
Rated C on Competitive Edge
Rated C on Growth Potential
Rated D+ on Differentiation

Industries

Biotechnology

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$69.4M

Headquarters

Rockville, Maryland

Founded

1996

Get referred to OriGene Technologies

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • OriGene launched EV Isolation Reagent and CD9 Exosome ELISA on March 23, 2026.
  • Its August 2026 site highlights broad Simple Western antibody coverage in EV, AAV, oncology.
  • The November 2025 ProteanFect distributorship adds transfection exposure beyond catalog reagents.

What critics are saying

  • August 31, 2026 image-integrity review exposed 2,236 flagged validation images, hurting trust.
  • Nature’s August 25, 2026 report linked OriGene to widespread antibody-image manipulation scrutiny.
  • If validation credibility erodes, academic buyers switch to Abcam, Thermo Fisher, and Bio-Techne.

What makes OriGene Technologies unique

  • OriGene’s September 2026 catalog lists 1,138,382 products across clones, antibodies, proteins.
  • Its June 2025 capability page claims 586K full-length human cDNA clones.
  • KO validation and Simple Western-optimized antibodies anchor its validation-heavy selling proposition.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$69.4M

Below

Industry Average

Funded Over

4 Rounds

Notable Investors:
Late VC funding comparison data is currently unavailable. We're working to provide this information soon!
Late VC Funding Comparison
Coming Soon

Benefits

Mentorship Program

Professional Development Budget

Conference Attendance Budget

Training Programs

Professional Certification Support

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↑ 1%

2 year growth

↑ 3%
OriGene Technologies Inc.
Nov 9th, 2023
CytoSections™ - Use case for antibody validation of the IDH1(R132H) mutation in Glioblastomas

OriGene has developed a tool for antibody validation called CytoSections.

Recently Posted Jobs

Sign up to get curated job recommendations

OriGene Technologies is Hiring for 2 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →